| Activation of c-erbB-2 and prognosis in ovarian carcinoma. Comparison with histologic type, grade, and stage. | |
| | |
MedLine Citation:
|
PMID: 7906608 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Prior reports suggested that measuring c-erbB-2 activation in ovarian carcinomas might be valuable in predicting prognosis. The authors attempted to confirm these studies while specifically excluding tumors of low malignant potential. METHODS: The clinical and pathologic significance of c-erbB-2 oncogene activation was assessed in 56 ovarian carcinomas, none of which met histologic criteria for tumor of low malignant potential. RESULTS: By using an immunohistochemical technique previously validated in molecular studies, c-erbB-2 oncogene overexpression was identified in 10 of the 56 carcinomas but did not correlate with histologic type, histologic grade, International Federation of Gynecology and Obstetrics (FIGO) stage, or prognosis. Adverse prognostic factors included histologic type (serous carcinoma), high grade, and high stage (FIGO Stages III and IV). Grade and stage were highly correlated with each other and were more important prognostic indicators than histologic type. CONCLUSION: Measuring c-erbB-2 activation in ovarian carcinomas may not be of practical value in predicting prognosis when tumors of low malignant potential are excluded. |
| | |
Authors:
|
T P Singleton; T Perrone; G Oakley; G A Niehans; L Carson; S S Cha; J G Strickler |
Related Documents
:
|
16161048 - Altered patterns of transcription of the septin gene, sept9, in ovarian tumorigenesis. 16434898 - The tubal fimbria is a preferred site for early adenocarcinoma in women with familial o... 8585978 - Amplifications of proto-oncogenes in ovarian carcinoma. 2342728 - Clinical value of sialyl tn antigen in patients with gynecologic tumors. 9196588 - Hepatocellular carcinoma. 1222208 - Significance of precancerous lesions in the colon and rectum. |
Publication Detail:
|
Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Cancer Volume: 73 ISSN: 0008-543X ISO Abbreviation: Cancer Publication Date: 1994 Mar |
Date Detail:
|
Created Date: 1994-03-31 Completed Date: 1994-03-31 Revised Date: 2010-03-24 |
Medline Journal Info:
|
Nlm Unique ID: 0374236 Medline TA: Cancer Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 1460-6 Citation Subset: AIM; IM |
Affiliation:
|
Department of Laboratory Medicine and Pathology, University of Minnesota Hospital and Clinic, Minneapolis. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adenocarcinoma, Clear Cell
/
genetics,
mortality,
pathology Adenocarcinoma, Mucinous / genetics, mortality, pathology Carcinoma / genetics, mortality*, pathology* Carcinoma, Endometrioid / genetics, mortality, pathology Female Gene Expression Regulation, Neoplastic Humans Neoplasm Staging Ovarian Neoplasms / genetics, mortality*, pathology* Prognosis Proto-Oncogene Proteins / analysis* Receptor, Epidermal Growth Factor / analysis* Receptor, erbB-2 Tumor Markers, Biological / analysis* |
| Chemical | |
Reg. No./Substance:
|
0/Proto-Oncogene Proteins; 0/Tumor Markers, Biological; EC 2.7.10.1/Receptor, Epidermal Growth Factor; EC 2.7.10.1/Receptor, erbB-2 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Prevalence and significance of HER-2/neu expression in early epithelial ovarian cancer.
Next Document: Growth hormone, insulin, and somatostatin therapy of cancer cachexia.